SCHEMBL3373274

SCHEMBL3373274

CCCCCCC/C=C\CCCCCCCCOC

nearest known ligand 0.83

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LPAR3 Q9UBY5 4/20 0.55
LPAR2 Q9HBW0 3/20 0.55
LPAR1 Q92633 2/20 0.55
FAAH O00519 2/20 0.54
TRPV1 Q8NER1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3372850 1.00 LPAR3 (0.55) LPAR3LPAR2LPAR1FAAHTRPV1
SCHEMBL3376673 1.00 LPAR3 (0.55) LPAR3LPAR2LPAR1FAAHTRPV1
SCHEMBL13042286 1.00 LPAR3 (0.55) LPAR3LPAR2LPAR1FAAHTRPV1
SCHEMBL16869374 1.00 LPAR3 (0.55) LPAR3LPAR2LPAR1FAAHTRPV1
SCHEMBL10445605 1.00 LPAR3 (0.55) LPAR3LPAR2LPAR1FAAHTRPV1
SCHEMBL1989989 1.00 LPAR3 (0.55) LPAR3LPAR2LPAR1FAAHTRPV1
SCHEMBL1142285 1.00 LPAR3 (0.55) LPAR3LPAR2LPAR1FAAHTRPV1
SCHEMBL1142491 1.00 LPAR3 (0.55) LPAR3LPAR2LPAR1FAAHTRPV1
SCHEMBL21357426 1.00 LPAR3 (0.55) LPAR3LPAR2LPAR1FAAHTRPV1
SCHEMBL3371335 1.00 LPAR3 (0.55) LPAR3LPAR2LPAR1FAAHTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2201156-A2 BIOFUEL COMPOSITION AND MANUFACTURING PROCESS Busch, Rainer (US) 2010-06-30 EP claimed
WO-2009035689-A2 BIOFUEL COMPOSITION AND MANUFACTURING PROCESS BUSCH RAINER (US) 2009-03-19 WO claimed
US-20170135962-A1 NOVEL DIESTER AND TRIESTER BASED LOW MOLECULAR WEIGHT, BIODEGRADEABLE CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY SIRNA THERAPEUTICS, INC. (US) 2017-05-18 US disclosed
US-9402816-B2 Diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery SIMA THERAPEUTICS, INC. (US) 2016-08-02 US disclosed
US-20150133519-A1 NOVEL DIESTER AND TRIESTER BASED LOW MOLECULAR WEIGHT, BIODEGRADEABLE CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY BANK OF AMERICA, N.A. 2015-05-14 US disclosed
EP-2201156-A2 BIOFUEL COMPOSITION AND MANUFACTURING PROCESS Busch, Rainer (US) 2010-06-30 EP disclosed
WO-2009035689-A2 BIOFUEL COMPOSITION AND MANUFACTURING PROCESS BUSCH RAINER (US) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133519-A1 NOVEL DIESTER AND TRIESTER BASED LOW MOLECULAR WEIGHT, BIODEGRADEABLE CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY CYP46A1, CETP, LIPC LPAR3 52/4885LPAR2 105/4885LPAR1 82/4885
US-20170135962-A1 NOVEL DIESTER AND TRIESTER BASED LOW MOLECULAR WEIGHT, BIODEGRADEABLE CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY CYP46A1, CETP, LIPC LPAR3 52/4885LPAR2 105/4885LPAR1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.